Author(s) :

Mardochée Semine Monga, Nathan Majambu Bulaba, Moïse Lukovi Mbingu, Narcisse Basosila, Colette Ashande Masengo, Jeff Bekomo Iteku, Théophile Fundu Mbemba, Pius Tshimankinda Mpiana, Koto-te-Nyiwa Ngbolua.

Volume/Issue :

Abstract :

Alchornea cordifolia, a member of the Euphorbiaceae family native to tropical Africa, is widely used in traditional medicine to treat inflammatory, infectious, and hematological conditions, including sickle cell disease. A comprehensive review covering its ethnobotanical uses, phytochemical composition, and pharmacological activities was lacking. A systematic review compliant with the PRISMA 2020 guidelines was conducted on the literature published between 2000 and 2026. A total of 1,299 references were identified, and 64 studies were included after screening. The risk of bias was assessed using the SYRCLE, ROBINS-I, and AMSTAR-2 tools, as well as the CONSIDER criteria. A descriptive meta-analysis weighted according to risk of bias was also performed. The results demonstrate the strong pharmacological potential of Alchornea cordifolia. Its anti-inflammatory, antioxidant, and anti-sickle cell activities are confirmed by preclinical studies and attributed primarily to phenolic compounds, flavonoids, and triterpenoids. Alchornea cordifolia is a promising African medicinal plant. However, methodological heterogeneity and the lack of clinical trials limit the level of evidence. Standardized studies and clinical trials are essential to confirm its efficacy, safety, and potential in the development of new herbal medicines.

No. of Downloads :

0